Cargando…
Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary
Carcinomas of unknown primary (CUP) represent between 3 and 10% of malignancies. Treatment with nonspecific chemotherapy is commonly unhelpful and the median survival is between 3 and 6 months. Gene expression microarray (GEM) analysis has demonstrated that molecular signatures can aid in tumour cla...
Autores principales: | Bridgewater, J, van Laar, R, Floore, A, Van'T Veer, L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361712/ https://www.ncbi.nlm.nih.gov/pubmed/18414470 http://dx.doi.org/10.1038/sj.bjc.6604315 |
Ejemplares similares
-
Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary
por: Wang, Xin, et al.
Publicado: (2023) -
An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer
por: Van Laar, R K
Publicado: (2010) -
Development and validation of a plasma-based melanoma biomarker suitable for clinical use
por: Van Laar, Ryan, et al.
Publicado: (2018) -
A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer
por: Molloy, T J, et al.
Publicado: (2011) -
No common denominator for breast cancer lymph node metastasis
por: Weigelt, B, et al.
Publicado: (2005)